[어바웃 G] 코오롱티슈진, 바이오 승계 구도 막바지…美 현지점검 단계

Kolon Group's succession plan is entering a critical phase as the fourth-generation heir directly spearheads Kolon TissueGene's US board meetings, signaling a strategic pivot towards the impending commercialization of TG-C. The company's imminent challenge lies in navigating the complex FDA BLA process while simultaneously managing investor perceptions regarding massive non-cash accounting losses from convertible bonds, which paradoxically stem from heightened market expectations for the drug.